deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT01919086

Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma

Sponsor: Hartford Hospital

Conditions Multiple Myeloma (MM)
Interventions Bortezomib Dexamethasone Lenalidomide
Updated 19 times since 2017 Last updated: Feb 10, 2026 Started: Aug 6, 2013 Primary completion: May 16, 2024 Completion: May 16, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Multiple Myeloma (MM), this trial is completed. The trial is conducted by Hartford Hospital and has accumulated 19 data snapshots since 2013. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Mar 2017 · 28 days · monthly snapshot~Mar 2017 – ~Apr 2017 · 31 days · monthly snapshot~Apr 2017 – ~Mar 2018 · 11 months · monthly snapshot~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Mar 2019 · 9 months · monthly snapshot~Mar 2019 – ~Dec 2019 · 9 months · monthly snapshot~Dec 2019 – ~Oct 2020 · 10 months · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Dec 2021 · 9 months · monthly snapshot~Dec 2021 – ~May 2022 · 5 months · monthly snapshot~May 2022 – ~May 2023 · 12 months · monthly snapshot~May 2023 – ~Oct 2023 · 5 months · monthly snapshot~Oct 2023 – ~Jun 2024 · 8 months · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Mar 2026 · 18 months · monthly snapshot~Mar 2026 – present · 5 months · monthly snapshot

Change History

19 versions recorded

  1. Mar 2026 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Mar 2026 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Jun 2024 — Jul 2024 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  5. Oct 2023 — Jun 2024 [monthly]

    Active Not Recruiting PHASE2

▶ Show 14 earlier versions

  1. May 2023 — Oct 2023 [monthly]

    Active Not Recruiting PHASE2

  2. May 2022 — May 2023 [monthly]

    Active Not Recruiting PHASE2

  3. Dec 2021 — May 2022 [monthly]

    Active Not Recruiting PHASE2

  4. Mar 2021 — Dec 2021 [monthly]

    Active Not Recruiting PHASE2

  5. Jan 2021 — Mar 2021 [monthly]

    Active Not Recruiting PHASE2

  6. Oct 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

  7. Dec 2019 — Oct 2020 [monthly]

    Active Not Recruiting PHASE2

  8. Mar 2019 — Dec 2019 [monthly]

    Active Not Recruiting PHASE2

  9. Jun 2018 — Mar 2019 [monthly]

    Active Not Recruiting PHASE2

  10. Mar 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE2

  11. Apr 2017 — Mar 2018 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  12. Mar 2017 — Apr 2017 [monthly]

    Recruiting PHASE2

  13. Feb 2017 — Mar 2017 [monthly]

    Recruiting PHASE2

  14. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE2

    First recorded

Aug 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Hartford Hospital
  • Memorial Sloan Kettering Cancer Center
  • Millennium Pharmaceuticals, Inc.
Data source: Memorial Sloan Kettering Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations